Compare YRD & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | BNR |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 315.4M | 322.1M |
| IPO Year | 2015 | 2019 |
| Metric | YRD | BNR |
|---|---|---|
| Price | $3.86 | $26.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 11.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $136.32 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.54 | $2.18 |
| 52 Week High | $8.74 | $41.72 |
| Indicator | YRD | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 44.30 |
| Support Level | $3.80 | $7.99 |
| Resistance Level | $4.40 | $41.40 |
| Average True Range (ATR) | 0.16 | 1.95 |
| MACD | 0.03 | -0.97 |
| Stochastic Oscillator | 64.00 | 27.86 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.